Senzine’s goal is improved clinical precision and simplified management in health care. By preventing complications and enabling care staff to follow care guidelines and drug recommendations, TetraGraph® helps shorten hospitalizations and reduce the costs of health care.
Senzime’s development portfolio also includes innovative, patient-oriented solutions that enable automated and continuous measurement of biological compounds like glucose and lactate in the blood and tissues—CliniSenz® Analyzer and OnZurf® Probe.
Senzime’s vision is a world completely free of anesthesia-related complications. Senzime operates in growth markets that are currently worth in excess of SEK 10 billion in Europe and the US alone. The company’s shares are traded on Nasdaq First North Growth Market (ticker SEZI).

Showing the single result